You are here

Ren, Jun

Overview:

Jun Ren MD, PhD  joined Duke University as faculty from 2008. He has actively worked with Professor Kim Lyerly to create the global cancer programs featured on education and research on  cancer immunotherapy and cancer vaccinewith Capital University Cancer Center,Beijing, China. They have been keeping pursuing to set up the win-to-win platform thought overcoming these differences and difficulties between US and China since 2008. He and Kim Lyerly secured the transitional research for cancer immunotherapy and achieved clinical research success and expand the global academic prospectives  of Duke University.

Positions:

Visiting Scholar in the Comprehensive Cancer Center

Duke Cancer Institute
School of Medicine

Education:

Publications:

Quantitative proteome analysis of colorectal cancer-related differential proteins.

To evaluate a new strategy for profiling proteomic changes in colorectal cancer (CRC).We used laser capture microdissection (LCM) to obtain cells from 20 CRC and paired normal mucosal tissues. The differential proteins between the microdissected tumor cells and normal mucosa epithelia were analyzed by acetylation stable isotopic labeling coupled with L linear ion trap Fourier transform ion cyclotron resonance mass spectrometry (LTQ-FT MS). Western blotting was used to assess the differential expression of proteins. We used bioinformatics tools for cluster and ingenuity pathway analysis of the differential proteins.In total, 798 confident proteins were quantified and 137 proteins were differentially expressed by at least twofold, including 67 that were upregulated and 70 that were downregulated in cancer. Two differential proteins, solute carrier family 12 member 2 (SLC12A2) and Ras-related protein Rab-10, were validated by Western blotting, and the results were consistent with acetylation stable isotopic labeling analysis. According to gene ontology analysis, CRC-related differential proteins covered a wide range of subcellular locations and were involved in many biological processes. According to ingenuity pathway analysis of the differential proteins, the most relevant canonical pathway associated with CRC was the 14-3-3-mediated signaling pathway, and seven reliable functional networks including cellular growth and proliferation, amino acid metabolism, inflammatory response, embryonic development, carbohydrate metabolism, cellular assembly and organization, and cell morphology were obtained.Combination of LCM, acetylation stable isotopic labeling analysis and LTQ-FT MS is effective for profiling proteomic changes in CRC cells.

Authors
Zhang, Y; Liu, Y; Ye, Y; Shen, D; Zhang, H; Huang, H; Li, S; Wang, S; Ren, J
MLA Citation
Zhang, Y, Liu, Y, Ye, Y, Shen, D, Zhang, H, Huang, H, Li, S, Wang, S, and Ren, J. "Quantitative proteome analysis of colorectal cancer-related differential proteins." Journal of cancer research and clinical oncology 143.2 (February 2017): 233-241.
PMID
27659785
Source
epmc
Published In
Journal of Cancer Research and Clinical Oncology
Volume
143
Issue
2
Publish Date
2017
Start Page
233
End Page
241
DOI
10.1007/s00432-016-2274-5

MicroRNA miR-590-5p inhibits breast cancer cell stemness and metastasis by targeting SOX2.

SOX2 (Sry-related high-mobility box SOX-2) is a transcription factor, which is essential for maintaining the cancer cell stemness. However, the role of microRNAs targeting  SOX2 in cancer cell stemness remains unclear. We examined the effect of miR-590-5p, which targeted  SOX2, on the breast cancer cell stemness and metastasis.We predicted and screened microRNA targeting SOX2, and further investigated the regulatory role of miR-590-5p on the level of SOX2 with Western blot, luciferase reporting assay and qRT-PCR analysis. Flow cytometry was performed to detect the effect of miR-590-5p on the breast cancer stem cell population with ALDEFLUOR Assay. We inoculated the breast cancer cells transfected with or without miR-590-5p to NOD/SCID mice to detect the tumorigenicity in vivo. Finally, forty-nine pairs of breast cancer samples and adjacent noncancerous tissues were obtained, and immunohistochemistry (IHC) with SOX2 antibody and qRT-PCR assay were used to quantify the expression of miR-590-5p in breast cancer samples.miR-590-5p significantly downregulated the SOX2 protein expression, and inhibition of miR-590-5p increased SOX2 expression. The luciferase reporter assay indicated that miR-590-5p decreased the SOX2 3'UTR (3' untranslated region) reporter activity but not the luciferase activity of the mutant reporter, in which the binding sites for miR-590-5p were mutated. ALDEFLUOR Assay showed that miR-590-5p significantly decreased breast cancer stem cells population. NOD/SCID nude mice experiments indicated that miR-590-5p significantly inhibited tumorigenicity of breast cancer cells. IHC assay and qRT-PCR suggested that miR-590-5p expression was downregulated in breast cancer patients, and negatively correlated with SOX2.miR-590-5p inhibited breast cancer cell stemness through targeting SOX2. Our study indicated that miR-590-5p might be a useful strategy for breast cancer treatment.

Authors
Zhou, L; Zhao, L-C; Jiang, N; Wang, X-L; Zhou, X-N; Luo, X-L; Ren, J
MLA Citation
Zhou, L, Zhao, L-C, Jiang, N, Wang, X-L, Zhou, X-N, Luo, X-L, and Ren, J. "MicroRNA miR-590-5p inhibits breast cancer cell stemness and metastasis by targeting SOX2." European review for medical and pharmacological sciences 21.1 (January 2017): 87-94.
PMID
28121351
Source
epmc
Published In
European Review for Medical and Pharmacological Sciences
Volume
21
Issue
1
Publish Date
2017
Start Page
87
End Page
94

Abstract 3417: Peripheral CD8+CD28-suppressive T lymphocytes act as a prognosticator among breast cancer patients with adoptive T-cell immunotherapy

Authors
Song, Q; Ren, J; Yu, J; Wang, X; Zhou, X; Lyerly, HK
MLA Citation
Song, Q, Ren, J, Yu, J, Wang, X, Zhou, X, and Lyerly, HK. "Abstract 3417: Peripheral CD8+CD28-suppressive T lymphocytes act as a prognosticator among breast cancer patients with adoptive T-cell immunotherapy." July 15, 2016.
Source
crossref
Published In
Cancer Research
Volume
76
Issue
14 Supplement
Publish Date
2016
Start Page
3417
End Page
3417
DOI
10.1158/1538-7445.AM2016-3417

Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45).

The recent immunotherapy treatment on triple-negative breast cancer (TNBC) leads to the breakthrough assignation. In this study, we have tried the new combinations of specific chemo with DC-CIKs immunotherapy to treat those patients.Twenty-three metastatic anthracyclines and taxanes pretreated TNBC younger (mean 41.5 years) patients were initially mobilized with cyclophosphamide (3 g/m(2)) for the preparation of CD34(+) peripheral blood mononuclear cells as the resources for generating DC/CIKs and marrow function supports. All cases were subsequently experienced 2 cycles of chemotherapy with cyclophosphamide 3 g/m(2), thiotepa 150 mg/m(2), and carboplatin AUC = 6, Q4w. The patients then received 3 infusions of DC-CIKs at the chemo intervals and followed by maintenance therapy with oral cyclophosphamide 50 mg daily. The endpoints were progression-free survival and overall survival.The partial response rate was 13.0 %, stable and progressive disease rates were 56.5 and 30.4 %, respectively. The median PFS was 13.5 months (95 % confidence interval (CI) 10.1-16.9 months) and OS was 15.2 months (95 % CI 12.5-18.1 months). The most common serious adverse events were neutropenia (100.0 %) and anemia (69.7 %) but without treatment-related mortality.These data suggested that such combination therapy model be effective and safe for younger metastatic TNBC exposure to previous anthracyclines and taxanes based adjuvant chemotherapy.

Authors
Wang, X; Ren, J; Zhang, J; Yan, Y; Jiang, N; Yu, J; Di, L; Song, G; Che, L; Jia, J; Zhou, X; Yang, H; Lyerly, HK
MLA Citation
Wang, X, Ren, J, Zhang, J, Yan, Y, Jiang, N, Yu, J, Di, L, Song, G, Che, L, Jia, J, Zhou, X, Yang, H, and Lyerly, HK. "Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45)." Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 18.1 (January 2016): 82-87.
PMID
26266766
Source
epmc
Published In
Clinical and Translational Oncology
Volume
18
Issue
1
Publish Date
2016
Start Page
82
End Page
87
DOI
10.1007/s12094-015-1339-2

The prognostic value of peripheral CD4+CD25+ T lymphocytes among early stage and triple negative breast cancer patients receiving dendritic cells-cytokine induced killer cells infusion.

This study aimed to assess the prognostic value of CD4+CD25+ T lymphocyte in peripheral blood among breast cancer patients treated with adoptive T lymphocytes immunotherapy.217 patients participated in the follow-up study. CD4+CD25+ proportion was measured by flow cytometry in peripheral T cells. The median survival was estimated by Kaplan-Meier curve, Log-rank test and Cox hazard proportion regression model, between groups of CD4+CD25+ proportion more than 5% and less than or equal to 5% in peripheral T cells.Peripheral CD4+CD25+ T lymphocytes had not a relationship with progression-free survival. It was featured that above 5% peripheral CD4+CD25+ proportion of T cells was related with the median overall survival by a shorten of 51 months (p < 0.05) with the HR 1.65 (95%CI 1.04, 2.62). Above 5% CD4+CD25+proportion of T cells produced the HR to be 1.76 (95%CI 1.07, 2.87) In stage 0-II patients, and 3.59 (95%CI 1.05, 12.29) in triple negative breast cancer patients.Cellular immunity restoration recovered by adoptive T cell infusions which resulted in less proportion of peripheral CD4+CD25+T lymphocytes could be a potential prognostic indicator among early stage and triple negative patients.

Authors
Song, Q-K; Ren, J; Zhou, X-N; Wang, X-L; Song, G-H; Di, L-J; Yu, J; Hobeika, A; Morse, MA; Yuan, Y-H; Yang, H-B; Lyerly, HK
MLA Citation
Song, Q-K, Ren, J, Zhou, X-N, Wang, X-L, Song, G-H, Di, L-J, Yu, J, Hobeika, A, Morse, MA, Yuan, Y-H, Yang, H-B, and Lyerly, HK. "The prognostic value of peripheral CD4+CD25+ T lymphocytes among early stage and triple negative breast cancer patients receiving dendritic cells-cytokine induced killer cells infusion." Oncotarget 6.38 (December 2015): 41350-41359.
PMID
26462021
Source
epmc
Published In
Oncotarget
Volume
6
Issue
38
Publish Date
2015
Start Page
41350
End Page
41359
DOI
10.18632/oncotarget.5534

The prognostic values of CYP2B6 genetic polymorphisms and metastatic sites for advanced breast cancer patients treated with docetaxel and thiotepa.

This study investigated interactive effects of CYP2B6 genotypes and liver metastasis on the prognosis of metastatic breast cancer patients who received combined chemotherapy of docetaxel and thiotepa. Totally 153 patients were retrospectively genotyped rs8192719 (c.1294 + 53C > T) and rs2279343 (c.785A > G). Kaplan-Meier method and Cox Proportional Hazard Regression model were used to estimate the survival. Patients with liver metastasis had worsen prognosis, conferring a 2.26-fold high risk of progression and 1.93-fold high risk of death (p < 0.05). Both CT/TT genotype of rs8192719 (c.1294 +  3C > T) and AG genotype of rs2279343 (c.785A > G) prolonged survival (p < 0.05). Furthermore, among liver metastatic patients, AG genotype of rs2279343 (c.785A > G) was associated with a 47% reduced risk of death and a 6-month-longer overall survival (p < 0.05). Among non-liver metastatic patients, hazard ratios of CT/TT genotype of rs8192719 (c.1294 + 53C > T) were 0.45 for progression and 0.40 for death; and the corresponding survival was improved by 6 months and 16 months, respectively (p < 0.05). Genotypes of CYP2B6 had an interaction with clinical efficacy of docetaxel and thiotepa on metastatic breast cancer patients; and metastatic sites also affected clinical responses. Further therapies should take into account of chemotherapy regimen, genotypes of metabolizing enzymes and metastatic sites for the particular subpopulation.

Authors
Song, Q; Zhou, X; Yu, J; Dong, N; Wang, X; Yang, H; Ren, J; Lyerly, HK
MLA Citation
Song, Q, Zhou, X, Yu, J, Dong, N, Wang, X, Yang, H, Ren, J, and Lyerly, HK. "The prognostic values of CYP2B6 genetic polymorphisms and metastatic sites for advanced breast cancer patients treated with docetaxel and thiotepa." Scientific reports 5 (November 25, 2015): 16775-.
PMID
26602960
Source
epmc
Published In
Scientific Reports
Volume
5
Publish Date
2015
Start Page
16775
DOI
10.1038/srep16775

Transformation of alkylating regimen of thiotepa into tepa determines the disease progression through GSTP1 gene polymorphism for metastatic breast cancer patients receiving thiotepa containing salvage chemotherapy.

The shifts to second-line chemotherapy for metastatic breast cancer (MBC) were widely required based on pharmaceutical molecular profiles to reach out precision medicine. The emerging precise treatment of cancer requires the implementation of clarified pharmacogenetic profiles which are capable of elucidating the predictive responses to cancer chemotherapy. Therefore we were interested in the analysis of the roles of single nucleotide polymorphism (SNP) of GSTP1 (glutathione S-transferase pi 1 gene) alleles to identify pharmacological links with predictors of clinical responses and toxicities.93 MBC patients receiving thiotepa plus docetaxel chemotherapy were enrolled in this study. Optimized CYP3A5, CYP2B6, and GSTP1 were predominantly selected as candidate genes and their three SNPs (CYP2B6 G516T, CYP3A5 A6986G, and GSTP1 A313G) were genotyped by matrix-assisted laser desorption ionization/time of flight (MALDI-TOF) mass spectrometry. Progression-free survival (PFS), disease control rate, and chemo-related toxicities were recorded.GSTP1 A313G (rs1695) was identified to be related with disease progression. In particular, patients harboring AG/GG genotype demonstrated a statistically longer PFS than those with AA. Multivariate analysis confirmed that AG/GG genotype was associated with both clinical responses and liver-localized metastatic lesions. No correlation was found between these three SNPs and chemotherapy-induced toxicity.These results suggest that the GSTP1 polymorphism is a novel prognostic marker for clinical response to thiotepa-containing chemotherapy regimens. Such evidence could provide insight into the role of pharmacogenetics to deprive of biases in shifting regimens solely by empirical choices.

Authors
Zhou, X; Wang, X; Song, Q; Yang, H; Zhu, X; Yu, J; Song, G; Di, L; Ren, J; Shao, H; Lyerly, HK
MLA Citation
Zhou, X, Wang, X, Song, Q, Yang, H, Zhu, X, Yu, J, Song, G, Di, L, Ren, J, Shao, H, and Lyerly, HK. "Transformation of alkylating regimen of thiotepa into tepa determines the disease progression through GSTP1 gene polymorphism for metastatic breast cancer patients receiving thiotepa containing salvage chemotherapy." International journal of clinical pharmacology and therapeutics 53.11 (November 2015): 914-922.
PMID
26396136
Source
epmc
Published In
International journal of clinical pharmacology and therapeutics
Volume
53
Issue
11
Publish Date
2015
Start Page
914
End Page
922
DOI
10.5414/cp202391

Breast Cancer Challenges and Screening in China: Lessons From Current Registry Data and Population Screening Studies.

As one of its responses to the increasing global burden of breast cancer (BC), China has deployed a national registration and BC screening campaign. The present report describes these programs and the initial results of these national BC control strategies, highlighting the challenges to be considered.The primary BC incidence and prevalence data were obtained from the Chinese National Central Cancer Registry. MapInfo software was used to map the geographic distribution and variation. The time trends were estimated by the annual percentage of change from 2003 to 2009. The description of the screening plans and preliminary results were provided by the Ministry of Health.Chinese cancer registries were primarily developed and activated in the East and Coastal regions of China, with only 12.5% of the registries located in West China. Geographic variation was noted, with the incidence of BC higher in North China than in South China and in urban areas compared with rural areas. Of great interest, these registries reported that the overall BC incidence has been increasing in China, with an earlier age of onset compared with Western countries and a peak incidence rate at age 50. In response to this increasing incidence and early age of onset, BC screening programs assessed 1.46 million women aged 35-59 years, using clinical breast examinations and ultrasound as primary screening tools between 2009 and 2011. The diagnostic rate for this screening program was only 48.0/10(5) with 440 cases of early stage BC. Early stage BC was detected in nearly 70% of screened patients. Subsequently, a second-generation screening program was conducted that included older women aged 35-64 years and an additional 6 million women were screened.The cancer registration system in China has been uneven, with a greater focus on East rather than West China. The data from these registries demonstrate regional variation, an increasing BC incidence, and an early age of onset. The 2009 to 2011 BC screening program targeting women aged 35-59 years had a low detection rate that resulted in a second-generation screening program that extended the cohort size and ages screened to 35-64 years.Cancer registration has been active in China for decades; however, a national survey of registries has not been routinely reported. This study used MapInfo to describe the reported data and found asymmetric registration activities, geographic variations in breast cancer (BC) burdens, and an increasing incidence with a peak at age 50. The initial Chinese BC screening programs focused on a relatively young population of women aged 35-59 years and had a low detection rate, but 69.7% of patients had early stage BC. Older women were included in the second-generation screening programs, and an additional 6 million women were screened. Consideration of regional variations and age is necessary to optimize the efficiency and utility of BC screening in China, with the ultimate goal to reduce BC mortality.

Authors
Song, Q-K; Wang, X-L; Zhou, X-N; Yang, H-B; Li, Y-C; Wu, J-P; Ren, J; Lyerly, HK
MLA Citation
Song, Q-K, Wang, X-L, Zhou, X-N, Yang, H-B, Li, Y-C, Wu, J-P, Ren, J, and Lyerly, HK. "Breast Cancer Challenges and Screening in China: Lessons From Current Registry Data and Population Screening Studies." The oncologist 20.7 (July 2015): 773-779.
PMID
26001390
Source
epmc
Published In
The oncologist
Volume
20
Issue
7
Publish Date
2015
Start Page
773
End Page
779
DOI
10.1634/theoncologist.2014-0351

Regional variation in identified cancer care needs of early-career oncologists in China, India, and Pakistan.

Cancer incidence and mortality is increasing in the developing world. Inequities between low-, middle-, and high-income countries affect disease burden and the infrastructure needs in response to cancer. We surveyed early-career oncologists attending workshops in clinical research in three countries with emerging economies about their perception of the evolving cancer burden.A cross-sectional survey questionnaire was distributed at clinical trial concept development workshops held in Beijing, Lahore, Karachi, and Mumbai at major hospitals to acquire information regarding home-country health conditions and needs.A total of 100 respondents participated in the workshops held at major hospitals in the region (India = 29, China = 25, Pakistan = 42, and other = 4). Expected consensus on many issues (e.g., emergence of cancer as a significant health issue) was balanced with significant variation in priorities, opportunities, and challenges. Chinese respondents prioritized improvements in cancer-specific care and palliative care, Indian respondents favored improved cancer detection and advancing research in cancer care, and Pakistani respondents prioritized awareness of cancer and improvements in disease detection and cancer care research. For all, the most frequently cited opportunity was help in improving professional cancer education and training.Predominantly early-career oncologists attending clinical research workshops (in China, India, and Pakistan) identified needs for increasing clinical cancer research, professional education, and public awareness of cancer. Decision makers supporting efforts to reduce the burden of cancer worldwide will need to factor the specific needs and aspirations of health care providers in their country in prioritizing health policies and budgets.

Authors
Lyerly, HK; Fawzy, MR; Aziz, Z; Nair, R; Pramesh, CS; Parmar, V; Parikh, PM; Jamal, R; Irumnaz, A; Ren, J; Stockler, MR; Abernethy, AP
MLA Citation
Lyerly, HK, Fawzy, MR, Aziz, Z, Nair, R, Pramesh, CS, Parmar, V, Parikh, PM, Jamal, R, Irumnaz, A, Ren, J, Stockler, MR, and Abernethy, AP. "Regional variation in identified cancer care needs of early-career oncologists in China, India, and Pakistan." The oncologist 20.5 (May 2015): 532-538.
PMID
25888267
Source
epmc
Published In
The oncologist
Volume
20
Issue
5
Publish Date
2015
Start Page
532
End Page
538
DOI
10.1634/theoncologist.2014-0213

Fruit Consumption Reduces the Risk of Esophageal Cancer in Yanting, People’s Republic of China

Authors
Song, Q; Zhao, L; Li, J; Ren, J
MLA Citation
Song, Q, Zhao, L, Li, J, and Ren, J. "Fruit Consumption Reduces the Risk of Esophageal Cancer in Yanting, People’s Republic of China." Asia Pacific Journal of Public Health 27.4 (May 2015): 469-475.
Source
crossref
Published In
Asia Pacific Journal of Public Health
Volume
27
Issue
4
Publish Date
2015
Start Page
469
End Page
475
DOI
10.1177/1010539514551199

A novel molecular marker of breast cancer stem cells identified by cell-SELEX method

Authors
Lu, M; Zhou, L; Zheng, X; Quan, Y; Wang, X; Zhou, X; Ren, J
MLA Citation
Lu, M, Zhou, L, Zheng, X, Quan, Y, Wang, X, Zhou, X, and Ren, J. "A novel molecular marker of breast cancer stem cells identified by cell-SELEX method." Cancer Biomarkers 15.2 (January 10, 2015): 163-170.
Source
crossref
Published In
Cancer biomarkers : section A of Disease markers
Volume
15
Issue
2
Publish Date
2015
Start Page
163
End Page
170
DOI
10.3233/CBM-140450

Continuous DC-CIK infusions restore CD8+ cellular immunity, physical activity and improve clinical efficacy in advanced cancer patients unresponsive to conventional treatments.

There are few choices for treatment of advanced cancer patients who do not respond to or tolerate conventional anti-cancer treatments. Therefore this study aimed to deploy the benefits and clinical efficacy of continuous dendritic cell-cytokine induced killer cell infusions in such patients.A total of 381 infusions (from 67 advanced cases recruited) were included in this study. All patients underwent peripheral blood mononuclear cell apheresis for the following cellular therapy and dendritic cells-cytokine induced killer cells were expanded in vitro. Peripheral blood T lymphocyte subsets were quantified through flow cytometry to address the cellular immunity status. Clinical efficacy and physical activities were evaluated by RECIST criteria and Eastern Cooperative Oncology Group scores respectively. Logistic regression model was used to estimate the association between cellular infusions and clinical benefits.An average of 5.7±2.94x10(9) induced cells were infused each time and patients were exposed to 6 infusions. Cellular immunity was improved in that cytotoxic CD8+CD28+T lymphocytes were increased by 74% and suppressive CD8+CD28-T lymphocytes were elevated by 16% (p<0.05). Continuous infusion of dendritic cells-cytokine induced killer cells was associated with improvement of both patient status and cellular immunity. A median of six infusions were capable of reducing risk of progression by 70% (95%CI 0.10-0.91). Every elevation of one ECOG score corresponded to a 3.90-fold higher progression risk (p<0.05) and 1% increase of CD8+CD28- T cell proportion reflecting a 5% higher risk of progression (p<0.05).In advanced cancer patients, continuous dendritic cell-cytokine induced killer cell infusions are capable of recovering cellular immunity, improving patient status and quality of life in those who are unresponsive to conventional cancer treatment.

Authors
Zhao, Y-J; Jiang, N; Song, Q-K; Wu, J-P; Song, Y-G; Zhang, H-M; Chen, F; Zhou, L; Wang, X-L; Zhou, X-N; Yang, H-B; Ren, J; Lyerly, HK
MLA Citation
Zhao, Y-J, Jiang, N, Song, Q-K, Wu, J-P, Song, Y-G, Zhang, H-M, Chen, F, Zhou, L, Wang, X-L, Zhou, X-N, Yang, H-B, Ren, J, and Lyerly, HK. "Continuous DC-CIK infusions restore CD8+ cellular immunity, physical activity and improve clinical efficacy in advanced cancer patients unresponsive to conventional treatments." Asian Pacific journal of cancer prevention : APJCP 16.6 (January 2015): 2419-2423.
PMID
25824775
Source
epmc
Published In
Asian Pacific journal of cancer prevention : APJCP
Volume
16
Issue
6
Publish Date
2015
Start Page
2419
End Page
2423

Detecting cell-in-cell structures in human tumor samples by E-cadherin/CD68/CD45 triple staining

Although Cell-in-cell structures (CICs) had been documented in human tumors for decades, it is unclear what types of CICs were formed largely due to low resolution of traditional way such as H&E staining. In this work, we employed immunofluorescent method to stain a panel of human tumor samples simultaneously with antibodies against E-cadherin for Epithelium, CD68 for Macrophage and CD45 for Leukocytes, which we termed as "EML method" based on the cells detected. Detail analysis revealed four types of CICs, with tumor cells or macrophage engulfing tumor cells or leukocytes respectively. Interestingly, tumor cells seem to be dominant over macrophage (93% vs 7%) as the engulfer cells in all CICs detected, whereas the overall amount of internalized tumor cells is comparable to that of internalized CD45(+) leukocytes (57% vs 43%). The CICs profiles vary from tumor to tumor, which may indicate different malignant stages and/or inflammatory conditions. Given the potential impacts different types of CICs might have on tumor growth, we therefore recommend EML analysis of tumor samples to clarify the correlation of CICs subtypes with clinical prognosis in future researches.

Authors
Huang, HY; Chen, A; Wang, T; Wang, MN; Ning, XK; He, MF; Hu, YZ; Yuan, L; Li, SC; Wang, QW; Liu, H; Chen, ZL; Ren, J; Sun, Q
MLA Citation
Huang, HY, Chen, A, Wang, T, Wang, MN, Ning, XK, He, MF, Hu, YZ, Yuan, L, Li, SC, Wang, QW, Liu, H, Chen, ZL, Ren, J, and Sun, Q. "Detecting cell-in-cell structures in human tumor samples by E-cadherin/CD68/CD45 triple staining." Oncotarget 6 (2015): 20278-20287.
Source
manual
Published In
Oncotarget
Volume
6
Publish Date
2015
Start Page
20278
End Page
20287

The Global Contribution of Outdoor Air Pollution to the Incidence, Prevalence, Mortality and Hospital Admission for Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis

Authors
Song, Q; Christiani, D; XiaorongWang, EY; Ren, J
MLA Citation
Song, Q, Christiani, D, XiaorongWang, EY, and Ren, J. "The Global Contribution of Outdoor Air Pollution to the Incidence, Prevalence, Mortality and Hospital Admission for Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis." International Journal of Environmental Research and Public Health 11.11 (November 2014): 11822-11832.
Source
crossref
Published In
International journal of environmental research and public health
Volume
11
Issue
11
Publish Date
2014
Start Page
11822
End Page
11832
DOI
10.3390/ijerph111111822

Oncogenicity of LHX4 in colorectal cancer through Wnt/β-catenin/TCF4 cascade

Authors
Cha, N; Liu, W; Yang, N; Xie, S; Gao, Y; Chen, X; Wang, X; Ren, J
MLA Citation
Cha, N, Liu, W, Yang, N, Xie, S, Gao, Y, Chen, X, Wang, X, and Ren, J. "Oncogenicity of LHX4 in colorectal cancer through Wnt/β-catenin/TCF4 cascade." Tumor Biology 35.10 (October 2014): 10319-10324.
Source
crossref
Published In
Tumor Biology
Volume
35
Issue
10
Publish Date
2014
Start Page
10319
End Page
10324
DOI
10.1007/s13277-014-2210-8

The relationship between methylenetetrahydrofolate reductase polymorphism and hematological malignancy.

BACKGROUND: Methylenetetrahydrofolate reductase (MTHFR) is the key enzyme for folate metabolism. Previous studies suggest a relationship between its single nucleotide polymorphisms (SNP) of C677T and A1298C with a variety of tumor susceptibility including hematological malignancy. SNP frequency distribution in different ethnic populations might lead to differences in disease susceptibility. There has been little research in Chinese people on the MTHFR SNP with the susceptibility of the hematological malignancy. Therefore, this study investigated the relationship between MTHFR SNPs and hematological malignancy in Jiangsu province in China. METHODS: Gene microarray was used to detect MTHFR C677T and A1298C single nucleotide polymorphism loci on 157 healthy controls and 127 patients from Jiangsu province with hematological malignancies (30 with multiple myeloma, 28 with non-Hodgkin's lymphoma, 22 with acute lymphoblastic leukemia, 40 with acute myeloid leukemia, and seven with chronic myeloid leukemia). RESULTS: The allele frequency of 677T was 41.3% in patients and 33.1% in controls, showed significant difference (chi2 = 4.08, p = 0.043); 677TT genotype with a high susceptibility to hematological malignancy (OR 1.96, 95% CI 1.01 - 4.45, p = 0.041). In subgroup analyses, the genotypes 677TT and 1298CC were associated with significantly increased multiple myeloma risk (TT vs. CC: OR 8.92, 95% CI 1.06 - 75.24, p = 0.006; CC vs. AA: OR = 4.80, 95% CI 1.56 - 14.73, p = 0.044). No associations were found between polymorphisms and susceptibilities to acute lymphoblastic leukemia, acute myeloid leukemia, or non-Hodgkin's lymphoma. CONCLUSIONS: MTHFRC677T polymorphisms influence the risk of hematological malignancy among the population in Jiangsu province. Both MTHFR 677TT and MTHFR 1298CC genotypes increase susceptibility to myeloid leukemia.

Authors
Jiang, N; Zhu, X; Zhang, H; Wang, X; Zhou, X; Gu, J; Chen, B; Ren, J
MLA Citation
Jiang, N, Zhu, X, Zhang, H, Wang, X, Zhou, X, Gu, J, Chen, B, and Ren, J. "The relationship between methylenetetrahydrofolate reductase polymorphism and hematological malignancy." Clinical laboratory 60.5 (January 2014): 767-774.
PMID
24839819
Source
epmc
Published In
Clinical laboratory
Volume
60
Issue
5
Publish Date
2014
Start Page
767
End Page
774

Mouse Flk-1(+) Sca-1(-) Mesenchymal Stem Cells: Functional Plasticity In Vitro and Immunoregulation In Vivo

Objectives Mesenchymal stem cells (MSCs) represent a powerful tool in regenerative medicine because of their differentiation and migration capacities. Moreover, the immunomodulatory ability of MSCs may be used to develop therapies for the treatment of autoimmune diseases. Methods In this study, we isolated Flk-1(+)Sca-1(-) MSCs from bone marrow (bMSCs). Next, we studied their biological characteristics and immunologic functions. We also investigated their effects on graft-versus-host disease (GVHD) associated with allogeneic bone marrow transplantation in mice. Results Flk-1(+)Sca-1(-) bMSCs were able to differentiate into fat and cartilage cells, indicating that the isolated cells had stem cell properties. They could also suppress alloantigen-induced T cell proliferation in vitro in a dose-dependent manner. Infusion of bMSCs into allogeneic bone marrow-transplanted mice alleviated the lethal GVHD that occurred in control recipient mice. There was significantly lower mortality among the recipients of the Flk-1(+)Sca-1(-) bMSCs that also ameliorated the clinical symptoms and GVHD histopathology. Beneficial effects on GVHD by Flk-1(+)Sca-1(-) bMSCs were also observed when MSCs were engineered to express anti-inflammatory cytokines IL-4 and IL-10 and decrease expression of proinflammatory cytokines IFN-, TNF-, and IL-2. Conclusion Flk-1(+)Sca-1(-) bMSCs have stem cell properties and can efficiently ameliorate the GVHD associated with allogeneic bone marrow transplantation in mice.

Authors
Zhu, XS; Yu, HJ; He, BX; Zhou, XN; Jiang, N; Zhang, HM; Wang, XL; Ren, J
MLA Citation
Zhu, XS, Yu, HJ, He, BX, Zhou, XN, Jiang, N, Zhang, HM, Wang, XL, and Ren, J. "Mouse Flk-1(+) Sca-1(-) Mesenchymal Stem Cells: Functional Plasticity In Vitro and Immunoregulation In Vivo." Transplantation 97 (2014): 509-517.
Source
manual
Published In
Transplantation
Volume
97
Publish Date
2014
Start Page
509
End Page
517
DOI
10.1097/01.tp.0000442775.46133.38

Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences.

BACKGROUND: We hypothesized that combination of dendritic cell (DC) with autologous cytokine-induced killer (CIK) immunotherapy in setting of high-dose chemotherapy (HDC) would be effective for selected metastatic breast cancer (MBC) patients. PATIENTS AND METHODS: Our previous work showed thiotepa could eradicate breast cancer stem cells. From 2004 to 2009, 79 patients received standard dose chemotherapy (SDC) of 75 mg/m(2) docetaxel and 75 mg/m(2) thiotepa versus 87 patients of HDC + DC/CIK: 120 mg/m(2) docetaxel to mobilize peripheral CD34(+) progenitor cells, a sequence of HDC (120 mg/m(2) docetaxel, plus 175 mg/m(2) thiotepa) + DC/CIK, with or without 400 mg/m(2) carboplatin depending upon bone marrow function. The endpoints were response rates (RR), progression-free survival (PFS), and overall survival (OS). RESULTS: Compared with SDC, PFS and OS were improved in HDC + DC/CIK (median PFS 10.2 vs. 3.7 months, P < 0.001; median OS 33.1 vs. 15.2 months, P < 0.001). Patients of pre-menopausal, HDC as first-line treatment after metastasis, or with visceral metastasis showed prolonged PFS and OS. SDC group also achieved the similar response as previous reports. CONCLUSION: Our study demonstrated the novel combination of HDC with DC/CIK to be an effective choice for the selected MBC population, in which choosing appropriate chemo regimens played important roles, and also specific HDC regimen plus DC/CIK immunotherapy showed the clinical benefits compared with chemotherapy alone.

Authors
Ren, J; Di, L; Song, G; Yu, J; Jia, J; Zhu, Y; Yan, Y; Jiang, H; Liang, X; Che, L; Zhang, J; Wan, F; Wang, X; Zhou, X; Lyerly, HK
MLA Citation
Ren, J, Di, L, Song, G, Yu, J, Jia, J, Zhu, Y, Yan, Y, Jiang, H, Liang, X, Che, L, Zhang, J, Wan, F, Wang, X, Zhou, X, and Lyerly, HK. "Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences." Clin Transl Oncol 15.10 (October 2013): 780-788.
PMID
23359185
Source
pubmed
Published In
Clinical and Translational Oncology
Volume
15
Issue
10
Publish Date
2013
Start Page
780
End Page
788
DOI
10.1007/s12094-013-1001-9

Elevated level of peripheral CD8(+)CD28(-) T lymphocytes are an independent predictor of progression-free survival in patients with metastatic breast cancer during the course of chemotherapy.

PURPOSE: Suppression of cellular immunity resulting from tumorigenesis and/or therapy might promote cancer cells' growth, progression and invasion. Here, we explored whether T lymphocyte subtypes from peripheral blood of metastatic breast cancer (MBC) female patients could be used as alternative surrogate markers for cancer progress. Additionally, plasma levels of interleukin (IL)-2, IL-4, IL-6, IL-10, IFN-γ, and transforming growth factor-β1 were quantitated from MBC and healthy volunteers. EXPERIMENTAL DESIGN: This study included 89 female MBC patients during the post-salvage chemotherapy follow-up and 50 age- and sex-matched healthy volunteers as control. The percentages of T lymphocyte subpopulations from peripheral blood and plasma levels of cytokines were measured. RESULTS: Both CD8(+)CD28(-) and CD4(+)CD25(+) were elevated in MBC patients compared to the control cohort (P < 0.05). In contrast, CD3(+) and CD8(+)CD28(+)cells were significantly lower in MBC patients (P < 0.0001, P = 0.045, respectively). MBC patients had elevated levels of immunosuppressive cytokines IL-6 and IL-10. Patients with elevated CD8(+)CD28(-) and CD4(+)CD25(+) cells showed increased levels of IL-6, and only patients with elevated CD8(+)CD28(-) had decreased interferon-γ. Univariate analysis indicated increased CD3(+)CD4(+) or CD8(+)CD28(+)correlated with prolonged progression-free survival (PFS), while elevated CD8(+)CD28(-)associated with shorten PFS. The percent of CD8(+)CD28(-) T lymphocytes is an independent predictor for PFS through multivariate analysis. CONCLUSIONS: This study suggests that progressive elevated levels of CD8(+)CD28(-) suppressor T lymphocytes represent a novel independent predictor of PFS during post-chemotherapy follow-up.

Authors
Song, G; Wang, X; Jia, J; Yuan, Y; Wan, F; Zhou, X; Yang, H; Ren, J; Gu, J; Lyerly, HK
MLA Citation
Song, G, Wang, X, Jia, J, Yuan, Y, Wan, F, Zhou, X, Yang, H, Ren, J, Gu, J, and Lyerly, HK. "Elevated level of peripheral CD8(+)CD28(-) T lymphocytes are an independent predictor of progression-free survival in patients with metastatic breast cancer during the course of chemotherapy." Cancer Immunol Immunother 62.6 (June 2013): 1123-1130.
PMID
23604172
Source
pubmed
Published In
Cancer Immunology, Immunotherapy
Volume
62
Issue
6
Publish Date
2013
Start Page
1123
End Page
1130
DOI
10.1007/s00262-013-1424-8

Abstract 5298: Two distinctive single nucleotide polymorphisms determine liver metastases responses to docetaxel plus thiotepa for metastatic breast cancer patients.

Authors
Yu, J; Dong, N; Yan, Y; Shao, B; Di, L; Song, G; Che, L; Jia, J; Jiang, H; Liang, X; Zhu, Y; Wang, C; Zahng, J; Zhu, B; Zhou, X; Wang, X; Yang, H; Ren, J; Lyerly, HK
MLA Citation
Yu, J, Dong, N, Yan, Y, Shao, B, Di, L, Song, G, Che, L, Jia, J, Jiang, H, Liang, X, Zhu, Y, Wang, C, Zahng, J, Zhu, B, Zhou, X, Wang, X, Yang, H, Ren, J, and Lyerly, HK. "Abstract 5298: Two distinctive single nucleotide polymorphisms determine liver metastases responses to docetaxel plus thiotepa for metastatic breast cancer patients." April 15, 2013.
Source
crossref
Published In
Cancer Research
Volume
73
Issue
8 Supplement
Publish Date
2013
Start Page
5298
End Page
5298
DOI
10.1158/1538-7445.AM2013-5298

Impaired immunomodulatory function of chronic myeloid leukemia cancer stem cells and the possible mechanism involved in it

Authors
Xishan, Z; Xinna, Z; baoxin, H; Jun, R
MLA Citation
Xishan, Z, Xinna, Z, baoxin, H, and Jun, R. "Impaired immunomodulatory function of chronic myeloid leukemia cancer stem cells and the possible mechanism involved in it." Cancer Immunology, Immunotherapy 62.4 (April 2013): 689-703.
Source
crossref
Published In
Cancer Immunology, Immunotherapy
Volume
62
Issue
4
Publish Date
2013
Start Page
689
End Page
703
DOI
10.1007/s00262-012-1367-5

Impact of cell dissociation on identification of breast cancer stem cells

Authors
Quan, Y; Yan, Y; Wang, X; Fu, Q; Wang, W; Wu, J; Yang, G; Ren, J; Wang, Y
MLA Citation
Quan, Y, Yan, Y, Wang, X, Fu, Q, Wang, W, Wu, J, Yang, G, Ren, J, and Wang, Y. "Impact of cell dissociation on identification of breast cancer stem cells." Cancer Biomarkers 12.3 (March 7, 2013): 125-133.
Source
crossref
Published In
Cancer biomarkers : section A of Disease markers
Volume
12
Issue
3
Publish Date
2013
Start Page
125
End Page
133
DOI
10.3233/CBM-130300

Effects of transplanted bone-marrow-derived mesenchymal stem cells in animal models of acute hepatitis

Authors
Zhu, X; He, B; Zhou, X; Ren, J
MLA Citation
Zhu, X, He, B, Zhou, X, and Ren, J. "Effects of transplanted bone-marrow-derived mesenchymal stem cells in animal models of acute hepatitis." Cell and Tissue Research 351.3 (March 2013): 477-486.
Source
crossref
Published In
Cell and Tissue Research
Volume
351
Issue
3
Publish Date
2013
Start Page
477
End Page
486
DOI
10.1007/s00441-012-1524-3

Comparison of the effects of human adipose and bone marrow mesenchymal stem cells on T lymphocytes

Authors
Xishan, Z; Baoxin, H; Xinna, Z; Jun, R
MLA Citation
Xishan, Z, Baoxin, H, Xinna, Z, and Jun, R. "Comparison of the effects of human adipose and bone marrow mesenchymal stem cells on T lymphocytes." Cell Biology International 37.1 (January 2013): 11-18.
Source
crossref
Published In
Cell Biology International
Volume
37
Issue
1
Publish Date
2013
Start Page
11
End Page
18
DOI
10.1002/cbin.10002

CD44+/CD24- breast cancer cells isolated from MCF-7 cultures exhibit enhanced angiogenic properties.

BACKGROUND: Recent studies suggest that the relationship between cancer stem cells (CSCs) and the vascular niche may be bidirectional; the niche can support the growth and renewal of CSCs, and CSCs may contribute to the maintenance of the niche. There is little knowledge concerning the role of breast cancer stem cells in promoting tumor angiogenesis. AIM: For human breast cancers, CSCs have been shown to be associated with a CD44+/CD24- phenotype. We investigated the potential activities of CD44+/CD24- breast cancer stem cells in promoting tumor angiogenesis. METHODS: The expression of pro-angiogenic genes was determined by quantitative real-time RT-PCR. Endothelial cell migration assays were employed to evaluate effects of conditioned media from CD44+/CD24- on human umbilical vein endothelial cells. A chorioallantoic membrane (CAM) assay was used to study the potential of CD44+/CD24- cells to promote angiogenesis. RESULTS: In our study, CD44+/CD24- cells expressed elevated levels of pro-angiogenic factors compared with CD44+/CD24+ cells. CD44+/CD24- cell-conditioned media significantly increased endothelial cell migration. Breast cancer cell lines enriched with CD44+/CD24- cells were more pro-angiogenic in the CAM assay than those lacking a CD44+/CD24- subpopulation. CD44+/CD24- cells sorted from MCF-7 cell lines were more pro-angiogenic in a CAM assay than CD44+/CD24+ cells. Furthermore, the VEGF concentration was significantly higher in CD44+/CD24- cell-conditioned media than in CD44+/CD24+ cell-conditioned media. The pro-angiogenic effect of CD44+/CD24- cells on endothelial cells was abolished by bevacizumab. CONCLUSION: Our findings demonstrate that CD44+/CD24- breast cancer stem cells have substantial pro-angiogenic potential and activity. This provides new insights to explore in the development of targeted therapies.

Authors
Sun, H; Jia, J; Wang, X; Ma, B; Di, L; Song, G; Ren, J
MLA Citation
Sun, H, Jia, J, Wang, X, Ma, B, Di, L, Song, G, and Ren, J. "CD44+/CD24- breast cancer cells isolated from MCF-7 cultures exhibit enhanced angiogenic properties." Clin Transl Oncol 15.1 (January 2013): 46-54.
PMID
22855175
Source
pubmed
Published In
Clinical and Translational Oncology
Volume
15
Issue
1
Publish Date
2013
Start Page
46
End Page
54
DOI
10.1007/s12094-012-0891-2

Activation of sonic hedgehog signaling pathway is an independent potential prognosis predictor in human hepatocellular carcinoma patients

Authors
Che, L; Yuan, Y-H; Jia, J; Ren, J
MLA Citation
Che, L, Yuan, Y-H, Jia, J, and Ren, J. "Activation of sonic hedgehog signaling pathway is an independent potential prognosis predictor in human hepatocellular carcinoma patients." Chinese Journal of Cancer Research 24.4 (December 2012): 323-331.
Source
crossref
Published In
Chinese Journal of Cancer Research
Volume
24
Issue
4
Publish Date
2012
Start Page
323
End Page
331
DOI
10.1007/s11670-012-0271-z

Murine bone marrow stromal cells pulsed with homologous tumor-derived exosomes inhibit proliferation of liver cancer cells

Authors
Ma, B; Jiang, H; Jia, J; Di, L; Song, G; Yu, J; Zhu, Y; Lu, Z; Wang, X; Zhou, X; Ren, J
MLA Citation
Ma, B, Jiang, H, Jia, J, Di, L, Song, G, Yu, J, Zhu, Y, Lu, Z, Wang, X, Zhou, X, and Ren, J. "Murine bone marrow stromal cells pulsed with homologous tumor-derived exosomes inhibit proliferation of liver cancer cells." CLINICAL & TRANSLATIONAL ONCOLOGY 14.10 (October 2012): 764-773.
PMID
22855153
Source
wos-lite
Published In
Clinical and Translational Oncology
Volume
14
Issue
10
Publish Date
2012
Start Page
764
End Page
773
DOI
10.1007/s12094-012-0860-9

Clinical safety of induced CTL infusion through recombinant adeno-associated virus-transfected dendritic cell vaccination in Chinese cancer patients

Authors
Di, L; Zhu, Y; Jia, J; Yu, J; Song, G; Zhang, J; Che, L; Yang, H; Han, Y; Ma, B; Zhang, C; Yuan, Y; You, M; Wan, F; Wang, X; Zhou, X; Ren, J
MLA Citation
Di, L, Zhu, Y, Jia, J, Yu, J, Song, G, Zhang, J, Che, L, Yang, H, Han, Y, Ma, B, Zhang, C, Yuan, Y, You, M, Wan, F, Wang, X, Zhou, X, and Ren, J. "Clinical safety of induced CTL infusion through recombinant adeno-associated virus-transfected dendritic cell vaccination in Chinese cancer patients." Clinical and Translational Oncology 14.9 (September 2012): 675-681.
Source
crossref
Published In
Clinical and Translational Oncology
Volume
14
Issue
9
Publish Date
2012
Start Page
675
End Page
681
DOI
10.1007/s12094-012-0854-7

Conjunction of tumor cells with lymphocytes: Implications for tumor invasion and metastasis

Authors
Song, G; Ren, J; Stojadinovic, A; Chen, W; Sahab, Z; Fu, SW; Man, Y-G
MLA Citation
Song, G, Ren, J, Stojadinovic, A, Chen, W, Sahab, Z, Fu, SW, and Man, Y-G. "Conjunction of tumor cells with lymphocytes: Implications for tumor invasion and metastasis." Cancer Epidemiology 36.4 (August 2012): 354-363.
Source
crossref
Published In
Cancer Epidemiology: the international journal of cancer epidemiology, detection and prevention
Volume
36
Issue
4
Publish Date
2012
Start Page
354
End Page
363
DOI
10.1016/j.canep.2011.12.006

Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine

Authors
Dong, N; Yu, J; Wang, C; Zheng, X; Wang, Z; Di, L; Song, G; Zhu, B; Che, L; Jia, J; Jiang, H; Zhou, X; Wang, X; Ren, J
MLA Citation
Dong, N, Yu, J, Wang, C, Zheng, X, Wang, Z, Di, L, Song, G, Zhu, B, Che, L, Jia, J, Jiang, H, Zhou, X, Wang, X, and Ren, J. "Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine." Journal of Cancer Research and Clinical Oncology 138.7 (July 2012): 1197-1203.
Source
crossref
Published In
Journal of Cancer Research and Clinical Oncology
Volume
138
Issue
7
Publish Date
2012
Start Page
1197
End Page
1203
DOI
10.1007/s00432-012-1183-5

HER2-specific T lymphocytes kill both trastuzumab-resistant and trastuzumab-sensitive breast cell lines in vitro

Authors
Lin, X-L; Wang, X-L; Ma, B; Jia, J; Yan, Y; Di, L-J; Yuan, Y-H; Wan, F-L; Lu, Y-L; Liang, X; Shen, T; Ren, J
MLA Citation
Lin, X-L, Wang, X-L, Ma, B, Jia, J, Yan, Y, Di, L-J, Yuan, Y-H, Wan, F-L, Lu, Y-L, Liang, X, Shen, T, and Ren, J. "HER2-specific T lymphocytes kill both trastuzumab-resistant and trastuzumab-sensitive breast cell lines in vitro." Chinese Journal of Cancer Research 24.2 (June 2012): 143-150.
Source
crossref
Published In
Chinese Journal of Cancer Research
Volume
24
Issue
2
Publish Date
2012
Start Page
143
End Page
150
DOI
10.1007/s11670-012-0143-6

Recombinant human endostatin could eliminate the pro-angiogenesis priority of SP cells sorted from non-small cell lung cancer cells

Purpose: To ascertain the biologic significance of lung cancer Side population (SP) cells, which represent putative cancer stem cells (CSC) in the absence of consensus biomarkers for tumor-specific CSC. Materials and methods: We sorted and analyzed the angiogenic features of SP cells, isolated from tumor cell lines based on the exclusion of the DNA dye Hoechst 33342, from the NSCLC cell lines A549 and H460. Results: Compared with non-SP cells, mRNA of vascular endothelial growth factor (VEGF)-A, VEGF-B, angiopoietin (ang)-1, ang-2, fibroblast growth factor-2 (FGF-2), cyclooxygenase-2 (Cox-2) and interleukin-8 (IL-8) were over-expressed in SP cells accompanied by over-expression of ABCG2 and MDR1 mRNA. The supernatant of cultured SP cells could significantly induce migration of human umbilical vein endothelial cells, while recombinant human endostatin (Endostar 25®) could inhibit the migration. Conclusions: This study revealed that the NSCLC SP cells might represent CSCs and possess pro-angiogenic properties, and antiangiogenesis represent a potential therapy. © Federacion de Sociedades Españolas de Oncología (FESEO) 2012.

Authors
Cao, B; Jia, J; Ma, L; Di, L; Song, G; Yuan, Y; Ma, B; Zhu, Y; Yu, J; Wang, X; Zhou, X; Lyerly, HK; Ren, J
MLA Citation
Cao, B, Jia, J, Ma, L, Di, L, Song, G, Yuan, Y, Ma, B, Zhu, Y, Yu, J, Wang, X, Zhou, X, Lyerly, HK, and Ren, J. "Recombinant human endostatin could eliminate the pro-angiogenesis priority of SP cells sorted from non-small cell lung cancer cells." Clinical and Translational Oncology 14.8 (2012): 575-585.
PMID
22855139
Source
scival
Published In
Clinical and Translational Oncology
Volume
14
Issue
8
Publish Date
2012
Start Page
575
End Page
585
DOI
10.1007/s12094-012-0844-9

Non-genetic risk factors and predicting efficacy for docetaxel-drug-induced liver injury among metastatic breast cancer patients

Background and Aim: Docetaxel has been chosen as one of the most popular anticancer drugs in the treatment of breast cancer for more than a decade. There is increasingly awareness for the occurrence of docetaxel and/or docetaxel-drug-induced liver injury (DILI), although the underlying mechanism of occurrence and its risk factors remain unclear. Methods: We conducted a retrospective cohort study to identify non-genetic risk factors for docetaxel-DILI among 647 metastasis breast cancer patients treated with docetaxel-containing regimens. Results: Sixty-seven (10.36%) patients were diagnosed as docetaxel-DILI. By logistic regression analysis, premenopausal status (odds ratio [OR][95% confidence interval {CI}]=2.24 [1.30-3.87]), past hepatitis B virus (HBV) infections (OR [95% CI]=4.23 [1.57-11.42]), liver metastasis (OR [95% CI]=3.70 [2.16-6.34]). The predominant occurrence of DILI was seen in groups with docetaxel combination regimens. (OR [95% CI]=2.66 [1.59-4.55]). The potential increasing occurrence of docetaxel-DILI was associated with multiple risk factors in an exposure-response manner (P<0.001), and patients with more than three risk factors would be exposed to a 36.61-fold risk of DILI (95% CI=10.18-131.62). Further analysis by the risk score and area under the receiver-operator characteristic curve (AUC) showed that those four factors contributed to an AUC of 0.7536 (95% CI=0.70-0.81), with a predictive sensitivity of 74.63% and specificity of 65.17%. Conclusions: Docetaxel-DILI with a relatively higher incidence should be addressed among metastatic breast cancer patients. Four predominant risk factors, including premenopausal status, past HBV infection, liver metastasis, and docetaxel combination regimens, were potential predicators for DILI. © 2012 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd.

Authors
Wang, Z; Liang, X; Yu, J; Zheng, X; Zhu, Y; Yan, Y; Dong, N; Di, L; Song, G; Zhou, X; Wang, X; Yang, H; Ren, J; Lyerly, HK
MLA Citation
Wang, Z, Liang, X, Yu, J, Zheng, X, Zhu, Y, Yan, Y, Dong, N, Di, L, Song, G, Zhou, X, Wang, X, Yang, H, Ren, J, and Lyerly, HK. "Non-genetic risk factors and predicting efficacy for docetaxel-drug-induced liver injury among metastatic breast cancer patients." Journal of Gastroenterology and Hepatology (Australia) 27.8 (2012): 1348-1352.
PMID
22432938
Source
scival
Published In
Journal of Gastroenterology and Hepatology
Volume
27
Issue
8
Publish Date
2012
Start Page
1348
End Page
1352
DOI
10.1111/j.1440-1746.2012.07131.x

Specific genetic polymorphisms of IL10-592 AA and IL10-819 TT genotypes lead to the key role for inducing docetaxel-induced liver injury in breast cancer patients

Aim: This study was designed to explore the genetic polymorphism of IL-10 (-1082A/G, -592A/C, -819T/C), TNF-α (-308G/A) with susceptibility to docetaxel-induced liver injury (DILI) in Chinese breast cancer patients. Methods: The targeted genetic polymorphisms of IL10-1082G/A, IL10-592A/C, IL10-819T/C, TNF-308G/A from 40 patients with DILI were assayed by matrix-assisted laser desorption/ionization-time of flight of Sequenom. Results: AA genotype of IL10-592 and TT of IL10-819 significantly increased incidence of DILI (P = 0.005, OR = 3.137). No differences of TNF gene polymorphism between the two groups were seen. Conclusion: The genetic polymorphism of the IL10-592A/C AA genotype and IL10-819T/C TT genotype was predominantly conferred to the incidence of docetaxel-induced liver injury. © 2012 Federación de Sociedades Españolas de Oncología (FESEO).

Authors
Liang, X; Zhang, J; Zhu, Y; Lu, Y; Zhou, X; Wang, Z; Yu, J; Yan, Y; Di, L; Che, L; al, E
MLA Citation
Liang, X, Zhang, J, Zhu, Y, Lu, Y, Zhou, X, Wang, Z, Yu, J, Yan, Y, Di, L, Che, L, and al, E. "Specific genetic polymorphisms of IL10-592 AA and IL10-819 TT genotypes lead to the key role for inducing docetaxel-induced liver injury in breast cancer patients." Clinical and Translational Oncology (2012): 1-4.
PMID
23143946
Source
scival
Published In
Clinical and Translational Oncology
Publish Date
2012
Start Page
1
End Page
4
DOI
10.1007/s12094-012-0936-6

Mobilization of peripheral blood stem cells using regimen combining docetaxel with granulocyte colony-stimulating factor in breast cancer patients

Authors
Yu, J; Ren, J; Di, L-J; Song, G-H; Zhu, Y-L; Zhang, J; Liang, X; Che, L; Jiang, H-F; Jia, J; Zhang, C-R
MLA Citation
Yu, J, Ren, J, Di, L-J, Song, G-H, Zhu, Y-L, Zhang, J, Liang, X, Che, L, Jiang, H-F, Jia, J, and Zhang, C-R. "Mobilization of peripheral blood stem cells using regimen combining docetaxel with granulocyte colony-stimulating factor in breast cancer patients." Chinese Journal of Cancer Research 23.1 (March 2011): 49-53.
Source
crossref
Published In
Chinese Journal of Cancer Research
Volume
23
Issue
1
Publish Date
2011
Start Page
49
End Page
53
DOI
10.1007/s11670-011-0049-8

Decrease of peripheral blood CD8+/CD28-suppressor T cell followed by dentritic cells immunomodulation among metastatic breast cancer patients

Authors
Song, G-H; Ren, J; Di, L; Yu, J; Zhang, J; Shao, B; Jia, J; Sun, W
MLA Citation
Song, G-H, Ren, J, Di, L, Yu, J, Zhang, J, Shao, B, Jia, J, and Sun, W. "Decrease of peripheral blood CD8+/CD28-suppressor T cell followed by dentritic cells immunomodulation among metastatic breast cancer patients." Chinese Journal of Cancer Research 22.4 (December 2010): 310-315.
Source
crossref
Published In
Chinese Journal of Cancer Research
Volume
22
Issue
4
Publish Date
2010
Start Page
310
End Page
315
DOI
10.1007/s11670-010-0310-6

Involvement of Hepatopoietin Cn in the development of human hepatocellular carcinoma

Authors
Zhu, B-D; Li, X-L; Liu, Y; Chang, J; Liu, Y; Zhang, D-D; Wang, Q; Ren, J; Cui, C-P
MLA Citation
Zhu, B-D, Li, X-L, Liu, Y, Chang, J, Liu, Y, Zhang, D-D, Wang, Q, Ren, J, and Cui, C-P. "Involvement of Hepatopoietin Cn in the development of human hepatocellular carcinoma." Clinical & Experimental Metastasis 27.8 (December 2010): 571-580.
Source
crossref
Published In
Clinical & Experimental Metastasis
Volume
27
Issue
8
Publish Date
2010
Start Page
571
End Page
580
DOI
10.1007/s10585-010-9346-8

Circulating tumor cells in metastatic breast cancer: Monitoring response to chemotherapy and predicting progression-free survival

Authors
Cheng, J-P; Yan, Y; Wang, X-Y; Lu, Y-L; Yuan, Y-H; Wang, X-L; Jia, J; Ren, J
MLA Citation
Cheng, J-P, Yan, Y, Wang, X-Y, Lu, Y-L, Yuan, Y-H, Wang, X-L, Jia, J, and Ren, J. "Circulating tumor cells in metastatic breast cancer: Monitoring response to chemotherapy and predicting progression-free survival." Chinese Journal of Cancer Research 22.3 (September 2010): 201-210.
Source
crossref
Published In
Chinese Journal of Cancer Research
Volume
22
Issue
3
Publish Date
2010
Start Page
201
End Page
210
DOI
10.1007/s11670-010-0201-x

Low correspondence of EGFR mutations in tumor tissue and paired serum of non-small-cell lung cancer patients

Authors
Song, G-H; Ren, J; Zhang, L-J; Di, L-J; Yuan, Y-H; Yu, J; Jia, J
MLA Citation
Song, G-H, Ren, J, Zhang, L-J, Di, L-J, Yuan, Y-H, Yu, J, and Jia, J. "Low correspondence of EGFR mutations in tumor tissue and paired serum of non-small-cell lung cancer patients." Chinese Journal of Cancer Research 22.1 (March 2010): 27-31.
Source
crossref
Published In
Chinese Journal of Cancer Research
Volume
22
Issue
1
Publish Date
2010
Start Page
27
End Page
31
DOI
10.1007/s11670-010-0027-6

Detection of gastric carcinoma-associated MG7-Ag by serum immuno-PCR assay in a high-risk Chinese population, with implication for screening

Authors
Zhang, L; Ren, J; Pan, K; Ma, J; Li, J; Shen, L; Zhang, X; Li, J; Fan, D; Gail, M; You, W
MLA Citation
Zhang, L, Ren, J, Pan, K, Ma, J, Li, J, Shen, L, Zhang, X, Li, J, Fan, D, Gail, M, and You, W. "Detection of gastric carcinoma-associated MG7-Ag by serum immuno-PCR assay in a high-risk Chinese population, with implication for screening." International Journal of Cancer 126.2 (January 15, 2010): 469-473.
Source
crossref
Published In
International Journal of Cancer
Volume
126
Issue
2
Publish Date
2010
Start Page
469
End Page
473
DOI
10.1002/ijc.24739

Dendritic cells pulsed with α-fetoprotein and mutant P53 fused gene induce bi-targeted cytotoxic T lymphocyte response against hepatic carcinoma

Authors
Ren, J; Jia, J; Zhang, H; Zhang, L; Ma, B; Jiang, H; Di, L; Song, G; Yu, J
MLA Citation
Ren, J, Jia, J, Zhang, H, Zhang, L, Ma, B, Jiang, H, Di, L, Song, G, and Yu, J. "Dendritic cells pulsed with α-fetoprotein and mutant P53 fused gene induce bi-targeted cytotoxic T lymphocyte response against hepatic carcinoma." Cancer Science 99.7 (July 2008): 1420-1426.
Source
crossref
Published In
Cancer Science
Volume
99
Issue
7
Publish Date
2008
Start Page
1420
End Page
1426
DOI
10.1111/j.1349-7006.2008.00820.x

Synergic antiproliferative effect of DNA methyltransferase inhibitor in combination with anticancer drugs in gastric carcinoma.

Epigenetic alterations of DNA methylation play an important role in the regulation of gene expression associated with chemosensitivity of gastric carcinomas. With the aim of improving the chemotherapeutic efficacy of gastric carcinoma, the effect of DNA methyltransferase inhibitor, 5-aza-CdR, on the chemosensitivity of five anticancer drugs was investigated. Human gastric cancer cell lines, OCUM-2M and MKN-74, and five anticancer drugs, 5-FU, PTX, OXA, SN38, and GEM, were used. In both gastric cancer cell lines, a synergistic antiproliferative effect by a combination of 5-aza-CdR at 5 microM was found in SN38 and GEM. 5-Aza-CdR at 5 microM increased apoptosis induced by SN38 and GEM in both cell lines. 5-Aza-CdR increases the expression of DAPK-2 and DAPK-3, RASSF1, and THBS1 genes in both OCUM-2M and MKN-74 cells, but not that of hMLH1, p16, MGMT, E-cadherin, and p53 genes. These findings suggest that 5-aza-CdR is a promising chemotherapeutical agent for gastric carcinomas, in combination with the anticancer drugs SN38 and GEM, in apoptosis signaling. The upregulation of DAPK-2 and DAPK-3, RASSF1, and THBS1 genes by 5-aza-CdR might be associated with the synergistic effect.

Authors
Zhang, X; Yashiro, M; Ohira, M; Ren, J; Hirakawa, K
MLA Citation
Zhang, X, Yashiro, M, Ohira, M, Ren, J, and Hirakawa, K. "Synergic antiproliferative effect of DNA methyltransferase inhibitor in combination with anticancer drugs in gastric carcinoma." Cancer science 97.9 (September 2006): 938-944.
PMID
16805821
Source
epmc
Published In
Cancer Science
Volume
97
Issue
9
Publish Date
2006
Start Page
938
End Page
944
DOI
10.1111/j.1349-7006.2006.00253.x

Dendritic cell generated from CD34+ hematopoietic progenitors can be transfected with adenovirus containing gene of HBsAg and induce antigen-specific cytotoxic T cell responses

Authors
Yang, J-Y; Cao, D-Y; Liu, W-C; Zhang, H-M; Teng, Z-H; Ren, J
MLA Citation
Yang, J-Y, Cao, D-Y, Liu, W-C, Zhang, H-M, Teng, Z-H, and Ren, J. "Dendritic cell generated from CD34+ hematopoietic progenitors can be transfected with adenovirus containing gene of HBsAg and induce antigen-specific cytotoxic T cell responses." Cellular Immunology 240.1 (March 2006): 14-21.
Source
crossref
Published In
Cellular Immunology
Volume
240
Issue
1
Publish Date
2006
Start Page
14
End Page
21
DOI
10.1016/j.cellimm.2006.06.005

Induction of α-fetoprotein-specific CD4- and CD8-mediated T-cell response using RNA-transfected dendritic cells

Authors
Zhang, H-M; Zhang, L-W; Ren, J; Fan, L; Si, X-M; Liu, W-C
MLA Citation
Zhang, H-M, Zhang, L-W, Ren, J, Fan, L, Si, X-M, and Liu, W-C. "Induction of α-fetoprotein-specific CD4- and CD8-mediated T-cell response using RNA-transfected dendritic cells." Cellular Immunology 239.2 (February 2006): 144-150.
Source
crossref
Published In
Cellular Immunology
Volume
239
Issue
2
Publish Date
2006
Start Page
144
End Page
150
DOI
10.1016/j.cellimm.2006.05.004

Comparative analysis of DC fused with tumor cells or transfected with tumor total RNA as potential cancer vaccines against hepatocellular carcinoma

Authors
Zhang, H-M; Zhang, L-W; Liu, W-C; Cheng, J; Si, X-M; Ren, J
MLA Citation
Zhang, H-M, Zhang, L-W, Liu, W-C, Cheng, J, Si, X-M, and Ren, J. "Comparative analysis of DC fused with tumor cells or transfected with tumor total RNA as potential cancer vaccines against hepatocellular carcinoma." Cytotherapy 8.6 (2006): 580-588.
Source
crossref
Published In
Cytotherapy (Informa)
Volume
8
Issue
6
Publish Date
2006
Start Page
580
End Page
588
DOI
10.1080/14653240600991353

Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines

Epigenetic alterations of the histone acetylation play an important role in the regulation of gene expression associated with cell cycles and apoptosis that may affect the chemosensitivity of gastric carcinomas. Recently, a histone deacetylase inhibitor, trichostatin A (TSA), was proven to be a chemo-sensitizer on human erythroleukemia cells. With the aim of improving the chemotherapeutic efficacy of gastric carcinoma, the effect of TSA on the chemosensitivity of several anticancer drugs in gastric carcinoma cells was investigated. Human gastric cancer cell lines, OCUM-8 and MKN-74, and 5 anticancer drugs, 5-fluorouracil (5-FU), paclitaxel (PTX), oxaliplatin (OXA), irinotecan (SN38) and gemcitabine (GEM) were used. In both gastric cancer cell lines, a synergistic anti-proliferative effect by the combination of TSA (30 ng/ml) with 5-FU, PTX or SN38 showed a synergistic anti-proliferative effect in OCUM-8 and MKN-74 cells. TSA increases the expression of p21, p53, DAPK-1 and the DAPK-2 gene in both OCUM-8 and MKN-74 cells. In conclusion, TSA is a promising chemotherapeutical agent in combination with anticancer drugs of 5-FU, PTX and SN38 in gastric cancer cell lines. The up-regulation of p53, p21, DAPK-1 and DAPK-2 might be associated with the synergistic effect of TSA.

Authors
Zhang, XT; Yashiro, M; Ren, J; Hirakawa, K
MLA Citation
Zhang, XT, Yashiro, M, Ren, J, and Hirakawa, K. "Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines." Oncology Reports 16 (2006): 563-568.
Source
manual
Published In
Oncology Reports: an international journal devoted to fundamental and applied research in oncology
Volume
16
Publish Date
2006
Start Page
563
End Page
568

Specific antihepatocellular carcinoma T cells generated by dendritic cells pulsed with hepatocellular carcinoma cell line HepG2 total RNA

Authors
Zhang, L; Zhang, H; Liu, W; Wang, H; Jia, J; Si, X; Ren, J
MLA Citation
Zhang, L, Zhang, H, Liu, W, Wang, H, Jia, J, Si, X, and Ren, J. "Specific antihepatocellular carcinoma T cells generated by dendritic cells pulsed with hepatocellular carcinoma cell line HepG2 total RNA." Cellular Immunology 238.1 (November 2005): 61-66.
Source
crossref
Published In
Cellular Immunology
Volume
238
Issue
1
Publish Date
2005
Start Page
61
End Page
66
DOI
10.1016/j.cellimm.2006.01.003

Oral Xeloda plus bi-platinu two-way combined chemotherapy in treatment of advanced gastrointestinal malignancies

AIM: To compare the effect, adverse events, cost-effectiveness and dose intensity (DI) of oral Xeloda vs calcium folinate (CF)/5-FU combination chemotherapy in patients with advanced gastrointestinal malignancies, both combined with bi-platinu two-way chemotherapy. METHODS: A total of 131 patients were enrolled and randomly selected to receive either oral Xeloda (X group) or CF/5-FU (control group). Oral Xeloda 1 000 mg/m(2) was administered twice daily from d 1 to 14 in X group, while CF 200 mg/m(2) was taken as a 2-h intravenous infusion followed by 5-FU 600 mg/m(2) intravenously for 4-6 h on d 1-5 in control group. Cisplatin and oxaliplatin were administered in the same way to both the groups: cisplatin 60-80 mg/m(2) by hyperthermic intraperitoneal administration, and oxaliplatin 130 mg/m(2) intravenously for 2 h on d 1. All the drugs were recycled every 21 d, with at least two cycles. Pyridoxine 50 mg was given t.i.d. orally for prophylaxis of the hand-foot syndrome (HFS). Then the effect, adverse events, cost-effectiveness and DI of the two groups were evaluated. RESULTS: Hundred and fourteen cases (87.0%) finished more than two chemotherapy cycles. The overall response rate of them was 52.5% (X group) and 42.4% (control group) respectively. Tumor progression time (TTP) was 7.35 mo vs 5.95 mo, and 1-year survival rate was 53.1% vs 44.5%. There was a remarkable statistical significance of TTP and 1-year survival between the two groups. The main Xeloda-related adverse events were myelosuppression, gastrointestinal toxicity, neurotoxicity and HFS, which were mild and well tolerable. Therefore, no patients withdrew from the study due to side effects before two chemotherapy cycles were finished. Both groups finished pre-arranged DI and the relative DI was nearly 1.0. The average cost for 1 patient in one cycle was (sic)9 137.35 (X group) and (sic)8 961.72 (control group), or US $1 100.89 in X group and $1 079.73 in control group. To add 1% to the response rate costs (sic)161.44 vs (sic)210.37 respectively (US $19.45 vs $25.35). One-month prolongation of TTP costs (sic)1 243.18 vs (sic)1 506.17 (US $149.78 vs $181.47). Escalation of 1% of 1-year survival costs (sic)172.74 vs (sic)201.64 (US $20.75 vs $24.29). CONCLUSION: Oral Xeloda combined with bi-platinu two-way combination chemotherapy is efficient and tolerable for patients with advanced gastrointestinal malignancies; meanwhile the expenditure is similar to that of CF/5-FU combined with bi-platinu chemotherapy, and will be cheaper if we are concerned about the increase of the response rate, TTP or 1-year-survival rate pharmacoeconomically. (C) 2005 The WJG Press and Elsevier Inc. All rights reserved.

Authors
Fan, L; Liu, WC; Zhang, YJ; Ren, J; Pan, BR; Liu, DH; Chen, Y; Yu, ZC
MLA Citation
Fan, L, Liu, WC, Zhang, YJ, Ren, J, Pan, BR, Liu, DH, Chen, Y, and Yu, ZC. "Oral Xeloda plus bi-platinu two-way combined chemotherapy in treatment of advanced gastrointestinal malignancies." World Journal of Gastroenterology 11 (2005): 4300-4304.
Source
manual
Published In
World journal of gastroenterology : WJG
Volume
11
Publish Date
2005
Start Page
4300
End Page
4304

Pathological characteristics of gastric leiomyoblastoma

AIM: To determine the pathological characteristics of gastric leiomyoblastoma. METHODS: All tissues were obtained during surgery or gastroscopy. Tissue specimens for examination by light microscope were 1 cmx1 cmx1 cm in size, fixed in 40 g/L neutral buffered formaldehyde, embedded in paraffin, and stained with hematoxylin and eosin. The fresh tissues obtained for electron microscopy were 1 mmx1 mmx1 mm in size, and fixed in phosphate buffered 30 g/L glutaraldehyde, postfixed in 10 g/L osmium tetroxide and dehydrated in graded alcohol, embebbed in Epon 812. Ultrathin sections of 50 nm were stained with uranyl acetate and lead citrate and examined under a JEM-2000 EX transmission electron microscope. RESULTS: The most important histopathological feature of leiomyoblastoma was the predominance of large, rounded or polygonal cells with characteristic perinuclear clear zone in cytoplasms. The tumor cells arranged in patch, cell junction or junctional complex could be found occasionally between cells under electron microscope. Most of the neoplastic cytoplasms were filled with myofilaments, dense bodies, and dense patches. Rough endoplasmic reticulum dilatated as lakes, and large quantities of protein secretions of intermediate electron density were found in the dilated cisternae. Intracisternal segregation could also be found. The nuclei were round or oval, and anomalous nuclei were found in part of cells. CONCLUSION: The diagnosis of gastric leiomyoblastoma can be confirmed by electron microscopy. The clear appearance of tumor cells is due to the dilation of rough endoplasmic reticulum, not fat droplets, glycogens or mucus in cytoplasm.

Authors
Huang, XF; Wang, CM; Pan, BR; Dai, XW; Fang, L; Yang, JJ; Yu, H; Ren, J
MLA Citation
Huang, XF, Wang, CM, Pan, BR, Dai, XW, Fang, L, Yang, JJ, Yu, H, and Ren, J. "Pathological characteristics of gastric leiomyoblastoma." World Journal of Gastroenterology 10 (2004): 3182-3184.
Source
manual
Published In
World journal of gastroenterology : WJG
Volume
10
Publish Date
2004
Start Page
3182
End Page
3184

Chinese literature associated with diagnosis of Helicobacter pylori

AIM: To synthetically analyze and probe into the diagnosis of H pylori infection, we followed the principles of evidence-based medicine. METHODS: A total of 22 papers of prevalence survey and case-control studies were selected for studying about diadynamic methods. Using meta-analysis, we analyzed the different diadynamic methods of H pylori in China. RESULTS: Through meta-analysis, among the five diadynamic methods, the accuracy of polymerase chain reaction (PCR) was the highest (98.47%) and PCR was the most sensitive method (Sp: 99.03%). CONCLUSION: Among the five diadynamic methods, the accuracy of PCR is the highest and PCR is the most sensitive method to diagnose the infection of H pylori.

Authors
Wan, Y; Xu, YY; Jiang, JH; Kong, FS; Xue, FB; Bai, YX; Pan, BR; Ren, J; Fan, DM
MLA Citation
Wan, Y, Xu, YY, Jiang, JH, Kong, FS, Xue, FB, Bai, YX, Pan, BR, Ren, J, and Fan, DM. "Chinese literature associated with diagnosis of Helicobacter pylori." World Journal of Gastroenterology 10 (2004): 231-233.
Source
manual
Published In
World journal of gastroenterology : WJG
Volume
10
Publish Date
2004
Start Page
231
End Page
233

CDH1 germline mutation in hereditary gastric carcinoma

This paper provides a bird's-eye view both in preclinical and clinical aspects of E-cadherin germline gene (CDH1) in gastric cancer patients and their families. E-cadherin, a product of CDH1 gene, belonging to the functionally related trans-membrane glycoprotein family, is responsible for the Ca(2+)-dependent cell-cell adhesion mechanism and contributes to dissociation followed by acquisition of cell motility, which usually occurs in the first step of cancer invasion and metastasis. CDH1 gene germline mutation is common in many types of carcinoma, and occurs very frequent in hereditary gastric carcinoma (HGC) patients and their families. Recently, more and more researches support that E-cadherin plays an important role in the differentiation, growth and invasion of HGC. So it is of great value to clarify its mechanisms both for understanding HGC pathogenesis and for clinical therapy, especially in China, where there are a high risk population of gastric cancer and a high HGC incidence rate. In this paper, recent researches on CDH1 gene mutation, especially its role in tumor genesis and progress of HGC, are reviewed, and advances in evaluation of its mutation status for HGC diagnosis, therapy and prognosis, are also discussed briefly.

Authors
Wang, HD; Ren, J; Zhang, L
MLA Citation
Wang, HD, Ren, J, and Zhang, L. "CDH1 germline mutation in hereditary gastric carcinoma." World Journal of Gastroenterology 10 (2004): 3088-3093.
Source
manual
Published In
World journal of gastroenterology : WJG
Volume
10
Publish Date
2004
Start Page
3088
End Page
3093

Construction and expression of recombined human AFP eukaryotic expression vector

AIM: To construct a recombined human AFP eukaryotic expression vector for the purpose of gene therapy and target therapy of hepatocellular carcinoma (HCC). METHODS: The full length AFP-cDNA of prokaryotic vector was digested, and subcloned to the multi-clony sites of the eukaryotic vector. The constructed vector was confirmed by enzymes digestion and electrophoresis, and the product expressed was detected by electrochemiluminescence and immunofluorescence methods. RESULTS: The full length AFP-cDNA successfully cloned to the eukaryotic vector through electrophoresis, 0.9723 IU/ ml AFP antigen was detected in the supernatant of AFPCHO by electrochemiluminescence method. Compared with the control groups, the differences were significant (P<0.05). AFP antigen molecule was observed in the plasma of AFPCHO by immunofluorescence staining. CONCLUSION: The recombined human AFP eukaryotic expression vector can express in CHO cell line. It provides experimental data for gene therapy and target therapy of hepatocellular carcinoma.

Authors
Zhang, LW; Ren, J; Zhang, L; Zhang, HM; Jin, B; Pan, BR; Si, XM; Zhang, YJ; Wang, ZH; Pan, YL; Festein, SM
MLA Citation
Zhang, LW, Ren, J, Zhang, L, Zhang, HM, Jin, B, Pan, BR, Si, XM, Zhang, YJ, Wang, ZH, Pan, YL, and Festein, SM. "Construction and expression of recombined human AFP eukaryotic expression vector." World Journal of Gastroenterology 9 (2003): 1465-1468.
Source
manual
Published In
World journal of gastroenterology : WJG
Volume
9
Publish Date
2003
Start Page
1465
End Page
1468

Detection of Circulating CEA Molecules in Human Sera and Leukopheresis of Peripheral Blood Stem Cells with E. coli Expressed Bispecific CEAScFv-Streptavidin Fusion Protein-Based Immuno-PCR Technique

Authors
REN, JUN; GE, LE; LI, YONGQI; BAI, JUN; LIU, WENCHAO; SI, XIAOMING
MLA Citation
REN, JUN, GE, LE, LI, YONGQI, BAI, JUN, LIU, WENCHAO, and SI, XIAOMING. "Detection of Circulating CEA Molecules in Human Sera and Leukopheresis of Peripheral Blood Stem Cells with E. coli Expressed Bispecific CEAScFv-Streptavidin Fusion Protein-Based Immuno-PCR Technique." Annals of the New York Academy of Sciences 945.1 (September 2001): 116-118.
Source
crossref
Published In
Annals of the New York Academy of Sciences
Volume
945
Issue
1
Publish Date
2001
Start Page
116
End Page
118
DOI
10.1111/j.1749-6632.2001.tb03871.x

Detection of circulating gastric cancer associated antigen MG7-Ag in human sera with McAb and bispecific ScFv-streptavidin fusion protein-based immuno-PCR technique

Authors
Ren, J; Liu, WC; Ge, L; Fan, DM; Yong, X
MLA Citation
Ren, J, Liu, WC, Ge, L, Fan, DM, and Yong, X. "Detection of circulating gastric cancer associated antigen MG7-Ag in human sera with McAb and bispecific ScFv-streptavidin fusion protein-based immuno-PCR technique." Clinical Chemistry 47 (2001): 366-366.
Source
manual
Published In
Clinical chemistry
Volume
47
Publish Date
2001
Start Page
366
End Page
366

Association of H-pylori infection with gastric carcinoma: a Meta analysis

AIM: To follow the principles of evidence based medicine to reach the integrated results of these studies. METHODS: Twenty-one papers of case-control studies were selected, including I I on gastric cancer, 7 on precancerous lesion of stomach and 3 on lymphoma of stomach. Meta analysis was used to sum up the odds ratios (OR) of these studies. RESULTS: H. pylori vsgastric cancer (intestinal and diffuse type): the odds ratio from the fixed effect model is 3.0016 (95% CI: 2.4197-3.7234, P < 0.001). H. pylori vs precancerous lesion of stomach: a random effect model was used to calculate the summary odds ratio and its value is 2.5635 (95% Cl: 1.8477-3.5566, P < 0.01). H. pylori vs lymphoma of stomach: though the quantity of literature is too small to make Meta analysis, the data of these 3 studies show that lymphoma of stomach is highly associated with H. pylori infections. CONCLUSION: Since it had been revealed that H. pylori infection pre-exists in gastric carcinoma and precancerous lesions, the results of Meta analysis present a strong evidence to support the conclusion that H. pylori infection is a risk factor for gastric carcinoma.

Authors
Xue, FB; Xu, YY; Wan, Y; Pan, BR; Ren, J; Fan, DM
MLA Citation
Xue, FB, Xu, YY, Wan, Y, Pan, BR, Ren, J, and Fan, DM. "Association of H-pylori infection with gastric carcinoma: a Meta analysis." World Journal of Gastroenterology 7 (2001): 801-804.
Source
manual
Published In
World journal of gastroenterology : WJG
Volume
7
Publish Date
2001
Start Page
801
End Page
804

Detection of circulating gastric carcinoma-associated antigen MG7-Ag in human sera using an established single determinant immuno-polymerase chain reaction technique

BACKGROUND. In 1994, a navel sensitive method termed immuno-polymerase chain reaction (PCR) for the detection of the gastric carcinoma-associated antigen MG7-Ag in the gastric carcinoma cell line KATO III was reported. Compared with the enzyme-linked immunoadsorbent assay, the single determinant immuno-PCR technique could allow for as few as 20 cells to be detected and was found to show an approximately 10,000-fold enhancement in sensitivity of the detection limit. The current study clinically evaluated the significance of serum MG7-Ag detection in gastric carcinoma patients. METHODS. The sera of patients were immobilized on wells and a specific DNA molecule, which could be amplified by PCR, was employed as a-marker. The biotinylated monoclonal antibody against gastric carcinoma was added to bind the antigen immobilized on the wells. After the biotinylated antibody was bound to the antigen, free avidin was used to attach a biotinylated nonoclonal antibody and biotinylated DNA molecule. The biotinylated DNA complexed with. antigen-antibody-avidin was amplified by PCR and the PCR products were analyzed by agarose gel electrophoresis. in the current study this method tvas used to detect circulating MG7-Ag in the sera of patients with gastric carcinoma and other various malignancies. For comparison, carcinoembryonic , CA.50, CA 19-9, and TAG-72 were quantitated by radioimmunoassay and immunoradiometric assay using the relevant commercial kits in the same sera samples from 86 patients with pathologically confirmed gastric carcinoma and 83;patients with relevant benign diseases of the stomach. In addition, the semiquantitative analysis of PCR products among gastric carcinoma patients with or without metastasis was performed to compare the intensity of DNA band amplification. RESULTS. Using the immuno-PCR assay, positive results were obtainer in 164 of 198 patients with gastric carcinoma (82.8%). The rates of positivity in other malignancies were 17.4% for esophageal carcinoma (15 of 86 patients), 44.4%for colonic carcfnoma (40 of 90 patients), 0% for liver carcinoma (none of 84 patients), 2.2% for ovarian carcinoma (1 of 45 patients), 0% for uterine carcinoma(none of 21 patients), and 6.1% for lung carcinoma (4 of 66 patients). The positive results obtained from those patients with benign diseases were 7.7% for peptic ulcer (6 of 78 patients), 5.9% for chronic gastritis (7 of 118 patients);, 3.3% for chronic colitis (2 of 60 patients), and 0.8% for healthy blood donors (2 of 236 patients). In addition, the semiquantitative analysis of PCR products showed that the intensity of DNA band amplified from the PCR products of those: patients with metastasis tvas much higher than that of patients without metastasis or those with early stage tumors (1.94 +/- 0.03 vs. 1.28 +/- 0.02). In comparative studies of immuno-PCR and commercial assays for tumor-associated antigens the sensitivity of immuno-PCR was 81.4% and pseudopositivity was lower (8.4% vs. 7.2-12.0% with radioimmunoassay or immunoradiometric assay). CONCLUSIONS. The results of the current study demonstrate that introducing PCR into the indirect determination of tumor-associated antigen in the serum can improve the sensitivity of detection greatly. This novel assay also might be used to monitor the circulating amount of tumor-associated antigen after gastrectomy and provide information regarding recurrence or metastasis, as well as for screening elderly patients who have no indications for endoscopy and those with precancerous conditions. The application of immuno-PCR in the serologic diagnosis of carcinoma has significant advantages including ready application in the clinical setting as well as use as a potential screening tool in mass surveys of high risk populations with gastric carcinoma. (C) 2000 American Cancer Society.

Authors
Ren, J; Chen, Z; Zhou, SJ; Zhang, XY; Pan, BR; Fan, DM
MLA Citation
Ren, J, Chen, Z, Zhou, SJ, Zhang, XY, Pan, BR, and Fan, DM. "Detection of circulating gastric carcinoma-associated antigen MG7-Ag in human sera using an established single determinant immuno-polymerase chain reaction technique." Cancer 88 (2000): 280-285.
Source
manual
Published In
Cancer
Volume
88
Publish Date
2000
Start Page
280
End Page
285
Show More